Ablexis
Ablexis develops and licenses the AlivaMab Mouse, a transgenic mouse platform enabling pharmaceutical and biotechnology companies to discover high-quality therapeutic antibody candidates. Its proprietary immunoglobulin transgenes and multiple mouse strains power direct licensing, with sister company AlivaMab Biologics providing fee-for-service discovery and engineering.
- Company typePrivate
- Founded2009
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Ablexis does
Ablexis is a privately-held biotechnology company that develops and licenses the AlivaMab Mouse, a next-generation transgenic mouse platform for the discovery of human therapeutic antibodies. Founded in 2009 by Larry Green, Ph.D. — a co-inventor of both XenoMouse and AlivaMab Mouse with over 25 years of experience in transgenic antibody platforms — the company has been owned by Deerfield Management since June 2018 and operates as a lean organization (1-10 employees) from San Diego, California. The core technology centers on synthetic, autonomously functioning immunoglobulin transgenes combining curated human VH, Vκ and Vλ gene segments with optimized regulatory elements, producing a part-human/part-mouse chimeric antibody composition that yields diverse, high-affinity IgG antibodies with favorable developability and reduced immunogenicity risk.
The company monetizes the platform through two complementary motions. First, non-exclusive licensing to pharmaceutical and biotechnology companies under three structures — perpetual, annual renewable, and individual target licenses — with upfront payments, development milestones, and royalties on product sales. Second, fee-for-service antibody discovery and engineering through sister company AlivaMab Biologics, which as of September 2025 offers license-, milestone-, and royalty-free access to the platform for partners that prefer outsourced discovery. The product portfolio has expanded from the original AlivaMab Mouse to include AlivaMab XKL Mouse (November 2022), AlivaMab Mouse-SDX for single domain discovery, and AlivaMab Mouse-NGX (September 2025), the latter delivering up to six times the number of antigen-specific antibodies versus comparator platforms.
Customer concentration skews toward global large-cap pharmaceutical companies — including AbbVie, Boehringer Ingelheim, Janssen, Eli Lilly, AstraZeneca (MedImmune), Novartis, Pfizer, and Teva — with additional licensed partners in biotechnology, cell therapy (Allogene), neurology (Voyager Therapeutics), dermatology (Almirall), and academic research. The platform is protected by an extensive international patent estate spanning the United States, Australia, Canada, Europe, Korea, and New Zealand. As of March 2026, 33 AlivaMab Mouse-derived antibody candidates were reported in clinical development — an 80% year-over-year increase — with at least two in pivotal Phase 3 trials, validating downstream commercial translation of licensees' programs.
Ablexis firmographics
Firmographics- Name
- Ablexis
- Legal name
- Ablexis, LLC
- Website
- https://ablexis.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Ablexis develops and licenses the AlivaMab Mouse, a transgenic mouse platform enabling pharmaceutical and biotechnology companies to discover high-quality therapeutic antibody candidates. Its proprietary immunoglobulin transgenes and multiple mouse strains power direct licensing, with sister company AlivaMab Biologics providing fee-for-service discovery and engineering.
- Ownership category
- akta.pro rank
Ablexis industry classification
Industry- Product category
- Therapeutic Antibody Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Ablexis is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Ablexis business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Technology Licensing: Non-exclusive licensing of AlivaMab Mouse platform to pharmaceutical and biotechnology companies for in-house antibody drug discovery. License types include perpetual non-exclusive licenses, annual renewable non-exclusive licenses, and individual target non-exclusive licenses. Revenue comes from upfront payments, development milestones, and royalty payments on product sales.
- Fee-for-Service Antibody Discovery: AlivaMab Biologics provides integrated antibody discovery and engineering services using AlivaMab Mouse platform on a fee-for-service basis. Services available milestone- and royalty-free for partners engaging for discovery services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Perpetual Non-Exclusive License |
| Subscription | Annual | Annual Renewable Non-Exclusive License |
| Transaction based/ take rate | Multi-year contract | Individual Target Non-Exclusive License |
| Other | Pay-as-you-go | Fee-for-Service Discovery |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Ablexis product offering
Product offeringCore offering
Ablexis develops and licenses the AlivaMab Mouse transgenic platform, a proprietary in vivo technology for the discovery of fully human therapeutic antibodies. The company licenses this platform to pharmaceutical and biotechnology companies and offers antibody discovery services through a sister company to support partners' therapeutic pipeline programs.
Product overview
Ablexis offers the AlivaMab Mouse, a next-generation transgenic mouse platform for human therapeutic antibody discovery, as both a licensable technology platform and through integrated discovery services. The product portfolio includes multiple AlivaMab Mouse strains (original AlivaMab Mouse, AlivaMab Mouse-NGX, AlivaMab XKL Mouse, and AlivaMab Mouse-SDX for single domain antibodies) that provide superior immune responses for efficient discovery of high-quality therapeutic antibody candidates. The company licenses the platform to pharmaceutical and biotech partners under flexible non-exclusive licensing models (annual, individual target, and perpetual), while sister company AlivaMab Discovery Services provides fee-for-service antibody discovery and engineering capabilities using these platforms.
Differentiator
Problem solved
Functional benefit
Products and services
- AlivaMab Mouse
- AlivaMab Mouse-NGX
- AlivaMab XKL Mouse
- AlivaMab Mouse-SDX
- AlivaMab Mouse Licensing
Quantifiable outcome
- 80% year-over-year increase in clinical candidates (33 total)
- +3 more outcomes
Companies that use Ablexis
Customer profileNamed customers14 records
Segments3 records
Ideal customer profiles1 record
Ablexis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Ablexis partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered major, core and flagship.
- AlmirallmajorMulti-target licensing agreement grants Almirall rights to use AlivaMab Mouse technology for discovery, development and commercialization of antibody drugs, combined with research partnership with AlivaMab Discovery Services for dermatology applications
- Tanabe Research Laboratories U.S.A.coreNon-exclusive multi-target license grants rights to use AlivaMab Mouse for antibody drug discovery, development and commercialization of antibody drug candidates discovered in pilot project
- JanssenmajorMulti-target discovery agreement with AlivaMab Discovery Services to generate and deliver therapeutic antibody candidates to Janssen for further evaluation
- Eli Lilly and CompanymajorExpanded non-exclusive perpetual license with broader rights including sublicensing to collaborators for antibody drug discovery projects
- Allogene TherapeuticscoreLicense grants rights to research, develop and commercialize AlivaMab antibodies against several targets for allogeneic CAR T (AlloCAR T) therapies for cancer
- Voyager TherapeuticscoreNon-exclusive license grants rights to use AlivaMab Mouse for antibody drug discovery and development, with potential for development milestones and royalty on product sales
- Memorial Sloan Kettering Cancer CentercoreLicense grants rights to research, develop and commercialize certain AlivaMab antibodies against a specific target, with rights to sublicense
- AbbViemajorLicensed AlivaMab Mouse for antibody drug discovery as part of major pharmaceutical partnership
- Boehringer IngelheimmajorLicensed AlivaMab Mouse for antibody drug discovery
- MedImmune (AstraZeneca)majorLicensed AlivaMab Mouse for antibody drug discovery
- NovartismajorLicensed AlivaMab Mouse for antibody drug discovery
- PfizermajorLicensed AlivaMab Mouse for antibody drug discovery
- TevamajorLicensed AlivaMab Mouse for antibody drug discovery
- Tri-Institutional Therapeutics Discovery InstitutecoreNon-exclusive license of AlivaMab Mouse for antibody discovery research
- AlivaMab Discovery ServicesflagshipSister company established to provide antibody discovery services leveraging AlivaMab Mouse platform. Founded in 2018 in response to partners wanting to outsource discovery to a scientifically-driven organization.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
Ablexis competitors and assessment
Company assessmentDirect peers
- Harbour BioMed: Harbour BioMed commercializes H2L2 and HCAb transgenic-mouse platforms for fully human and heavy-chain-only antibody discovery, respectively. The company offers both licensing and fee-for-service discovery similar to Ablexis's two-channel go-to-market model, serving overlapping pharma and biotech customers.
- Adimab: Adimab operates a yeast-based antibody-discovery platform that competes with transgenic-mouse approaches like AlivaMab Mouse. It serves large pharma (including several of Ablexis's licensees such as Eli Lilly and Novartis) and biotech with partnership-based discovery services and licensing.
- Trianni (an AbCellera company): Trianni's transgenic mouse platform (The Trianni Mouse) is a closely comparable antibody-discovery platform using human immunoglobulin gene segments. Like Ablexis, it licenses its technology to pharma for therapeutic antibody generation and was acquired by AbCellera in part to combine transgenic-mouse and single-cell screening capabilities.
- Kymab (a Sanofi company): Kymab operated the IntelliSelect transgenic-mouse antibody discovery platform and was acquired by Sanofi in 2021. It directly competed with Ablexis in licensing transgenic-mouse technology to pharma and biotech, including offering human antibody discovery for challenging targets.
- Ligand Pharmaceuticals (OmniAb): Ligand's OmniAb business is a direct transgenic-mouse antibody-discovery platform competitor. Like Ablexis, OmniAb offers licensing of multiple transgenic-mouse strains (OmniRat, OmniMouse, OmniChicken, OmniClic, OmniDolphin) to pharma and biotech partners for therapeutic antibody generation, with similar milestone/royalty economics.
- Distributed Bio (now part of Charles River Laboratories): Distributed Bio offered antibody-discovery platforms including the SuperHuman library and computational antibody optimization. Now part of Charles River Laboratories' discovery services, it competed with Ablexis for biotech and pharma antibody-discovery outsourcing business using in silico and library-based approaches.
Broad incumbents
- AbCellera Biologics: AbCellera is a publicly traded antibody-discovery company that combines single-cell screening with transgenic-mouse technology (via the Trianni acquisition). It competes with Ablexis across antibody discovery modalities and serves many of the same large pharma partners.
- GenScript ProBio: GenScript offers antibody-discovery services including proprietary platforms (e.g., single B-cell screening, phage display, and humanized mice) and serves pharma/biotech across the discovery value chain. It overlaps with Ablexis on fee-for-service antibody discovery, particularly through its premium-discovery offerings.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Ablexis social profiles
Digital presenceAblexis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ablexis leadership team
Management profileNumber of profiles
Profiles2 records
Ablexis subsidiaries and ownership
Company hierarchySubsidiaries1 record
Ablexis funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ablexis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ablexis
What does Ablexis do?
Ablexis develops and licenses the AlivaMab Mouse transgenic platform, a proprietary in vivo technology for the discovery of fully human therapeutic antibodies. The company licenses this platform to pharmaceutical and biotechnology companies and offers antibody discovery services through a sister company to support partners' therapeutic pipeline programs.
Is Ablexis a public or private company?
Ablexis is a private company. It is classified as unknown and is currently operating.
When was Ablexis founded?
Ablexis was founded in 2009. It employs 1 to 10 people.
Where is Ablexis based?
Ablexis is headquartered in San Francisco, United States, in the North America region.
How does Ablexis make money?
Two revenue lines are on record. Technology Licensing is the primary driver. The others are fee-for-Service Antibody Discovery.
Who are Ablexis's main competitors?
Direct peers on record are Harbour BioMed, Adimab, Trianni (an AbCellera company), Kymab (a Sanofi company), Ligand Pharmaceuticals (OmniAb) and Distributed Bio (now part of Charles River Laboratories). Broad incumbents are AbCellera Biologics and GenScript ProBio.
Does Ablexis have an API?
No public API is recorded for Ablexis.
What industry is Ablexis in?
Ablexis's product category is Therapeutic Antibody Discovery Platform. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.